Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 trial evaluating co-administration of ABT-493 and ABT-530 with and without RBV for chronic HCV genotypes 2-6; results posted in 2017…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-493
• ABT-530
• RBV (ribavirin)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C, Hepatitis C Virus | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-10-02